

Manuscript Number: CRYO-D-12-00073R1

Title: Clinical efflux of cryoprotective agents from vitrified human articular cartilage

Article Type: Research Paper

Keywords: articular cartilage, vitrification, cryoprotective agents, efflux, dilution, efflux

Corresponding Author: Dr. Nadr M Jomha, PhD, MD, FRCS(C)

Corresponding Author's Institution: University of Alberta

First Author: Hana Yu

Order of Authors: Hana Yu; Khaled K Al-Abbasi, MD; Janet A W Elliott, PhD; Locksley E McGann, PhD; Nadr M Jomha, PhD, MD, FRCS(C)

Abstract: In previous research, we successfully cryopreserved intact human articular cartilage on its bone base with high chondrocyte viability using a vitrification protocol that entailed sequential exposure to several cryopreserving agents (CPAs) at lowering temperatures resulting in a high final concentration of CPA. The CPA must be removed from the cartilage at warming due to its toxicity to cells in the cryopreserved tissue and the post-transplant adjacent tissues. The current experiment explores the relationship between removal solution volume and time required for complete removal of CPA from bone-cartilage samples.

Osteochondral dowels of 10mm diameter from five patients undergoing total knee arthroplasty were vitrified using our protocol resulting in 6.5M CPA within the matrix. In the primary experiment, the warmed dowels were immersed in 10ml of X-VIVO for 30min and this was repeated 5 times (the last wash being 5 min only). Removal solution osmolality was recorded at various times and compared to controls of pure X-VIVO. Changes in removal solution osmolality over time were normalized to tissue volume. In a secondary experiment, the procedure was repeated using double the volume of removal solution (20ml X-VIVO).

Results showed a rapid change in the osmolality of the removal solution indicating a rapid efflux of CPA from cartilage. The efflux rate decreased with time and during subsequent immersions until equilibrium was reached during the 4th immersion indicating effectively complete removal of CPA. Doubling the amount of removal solution demonstrated the effective removal of CPAs by the third immersion.

The results of this study yield a practical relationship between the amount of removal solution and the time and number of immersions required to remove CPA from the transplantable tissue.

NOTICE: this is the author's version of a work that was accepted for publication in *Cryobiology*. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in *Cryobiology*, Volume 66, Issue 2, April 2013, Pages 121-125. <http://dx.doi.org/10.1016/j.cryobiol.2012.12.005>.

1 Clinical efflux of cryoprotective agents from vitrified human articular cartilage

2 ±Hana Yu¹, ±Khaled K. Al-Abbasi¹, Janet AW Elliott^{2,3}, Locksley E McGann³, Nadr M.

3 Jomha¹

4

5 ¹Department of Surgery

6 University of Alberta

7 Edmonton, Canada

8

9 ²Department of Chemical and Materials Engineering

10 University of Alberta

11 Edmonton, Canada

12

13 ³Department of Laboratory Medicine and Pathology

14 University of Alberta

15 Edmonton, Canada

16

17 Corresponding author:

18 Nadr M Jomha

19 2D2.32 WMC Department of Surgery

20 University of Alberta Hospital

21 Edmonton, Alberta, Canada

22 T6G 2B7

23 Phone: 1 780 407 2816

24 Fax: 1 780 407 2819

25 Email: njomha@ualberta.ca

26

27 ± denotes co-first authorship

28 **Abstract**

29 In previous research, we successfully cryopreserved intact human articular cartilage on its
30 bone base with high chondrocyte viability using a vitrification protocol that entailed
31 sequential exposure to several cryopreserving agents (CPAs) at lowering temperatures
32 resulting in a high final concentration of CPA. The CPA must be removed from the
33 cartilage at warming due to its toxicity to cells in the cryopreserved tissue and the post-
34 transplant adjacent tissues. The current experiment explores the relationship between
35 removal solution volume and time required for complete removal of CPA from bone-
36 cartilage samples.

37 Osteochondral dowels of 10mm diameter from five patients undergoing total knee
38 arthroplasty were vitrified using our protocol resulting in 6.5M CPA within the matrix. In
39 the primary experiment, the warmed dowels were immersed in 10ml of X-VIVO for
40 30min and this was repeated 5 times (the last wash being 5 min only). Removal solution
41 osmolality was recorded at various times and compared to controls of pure X-VIVO.
42 Changes in removal solution osmolality over time were normalized to tissue volume. In a
43 secondary experiment, the procedure was repeated using double the volume of removal
44 solution (20ml X-VIVO).

45 Results showed a rapid change in the osmolality of the removal solution
46 indicating a rapid efflux of CPA from cartilage. The efflux rate decreased with time and
47 during subsequent immersions until equilibrium was reached during the 4th immersion
48 indicating effectively complete removal of CPA. Doubling the amount of removal
49 solution demonstrated the effective removal of CPAs by the third immersion.

50 The results of this study yield a practical relationship between the amount of
51 removal solution and the time and number of immersions required to remove CPA from
52 the transplantable tissue.

53

54

55 **Key Words:** articular cartilage, vitrification, cryoprotective agents, efflux, dilution

56 **Introduction**

57 Osteoarthritis is a massive burden on the health care system owing to its negative impact
58 on quality of life and functional productivity of those affected. Progressive joint
59 deterioration occurs with large cartilage defects[7]. Osteochondral allografting is one
60 treatment option that can treat the largest defects[8; 12; 13; 26] with advantages over
61 synthetic resurfacing techniques such as joint replacement because as biologic implants,
62 allografts can integrate with the host tissue and function indefinitely. Unfortunately, fresh
63 allografting is limited by tissue availability, difficulty matching the size and shape of the
64 required cartilage tissue, the risk of infection transmission, and the necessity of
65 transplantation within 48 to 72 hours.

66

67 To overcome these obstacles, investigations into effective methods of storing cartilage
68 have been pursued. Hypothermic storage of allografts in 4 °C can provide storage for 28-
69 42 days but cell deterioration begins after 7-14 days[5; 10; 29]. Classical
70 cryopreservation methods using low concentrations of CPAs and controlled freezing
71 showed some success when applied to chondrocytes in isolation[24], but resulted in low
72 cell recovery when applied to complex articular cartilage tissue[19]. Recently,
73 vitrification studies by various groups using high concentrations of CPAs and rapid
74 cooling resulted in excellent cell recovery in pig articular cartilage removed from the
75 bone[11], thin rabbit articular cartilage[25] and thin human articular cartilage removed
76 from bone[27]. Most recently, we have developed a vitrification protocol that
77 successfully cryopreserves intact human articular cartilage on a bone base with
78 approximately 75% cell recovery as determined by membrane integrity dyes, a metabolic

79 assay and a functional assay that demonstrates the vitrified cells can produce cartilage
80 specific collagen II and sulfated glycosaminoglycans[17]. Cryopreservation protocols are
81 usually referred to as “vitrification” protocols if they involve high concentration of CPAs
82 so that vitrification is the likely mechanism of cell protection, whether or not actual
83 complete vitrification of the tissue has been confirmed. In the case of our protocol, we
84 have verified that the final vitrification solution vitrifies, and does not devitrify, at the
85 relevant cooling and warming rates, as confirmed by visual inspection for ice[28]. The
86 cartilage cryopreserved with our vitrification protocol has the potential to be tissue
87 banked and transplanted.

88

89 The use of CPAs in sufficient concentration to vitrify biologic tissues can result in
90 cellular toxicity through different mechanisms. For example, dimethyl sulfoxide (Me₂SO)
91 alters the cell membrane permeability by blocking the Na⁺ and Ca²⁺ ion channels[9; 15],
92 alters mitochondrial membrane potential[31], and induces cellular apoptosis[22].
93 Glycerol causes mitochondrial dysfunction by acting on the glycerol phosphate cycle[14],
94 while ethylene glycol affects the ATP production, thereby affecting the biochemical
95 functions of the cell[16]. To minimize toxicity, combinations of multiple CPAs have been
96 used with each CPA at a lower concentration while still achieving an overall
97 concentration sufficient to vitrify[6; 11; 21; 25].

98

99 Successful cryopreservation of intact human articular cartilage was recently achieved
100 using a combination of 4 CPAs totaling 6.5M[17]. Prior to transplanting this tissue, the
101 CPAs must be removed to avoid cellular toxicity of local cells and possible side effects

102 on the recipient patient. In our previous work, CPA permeation into cartilage off the bone
103 was theoretically and experimentally studied[2; 3; 4; 20; 23], and for bone-cartilage
104 samples, chondrocyte viability and function was experimentally assessed after
105 cryopreservation, thaw and CPA removal[17]. Permeation and preservation of bone was
106 not studied because the bone will get resorbed and incorporated into the host tissue post-
107 transplantation and its viability is not required. However, for practical implementation of
108 cryopreserved cartilage tissue in a clinical setting, it is important to understand trade-offs
109 in different removal protocols for the entire bone-cartilage construct as will be used in
110 practice. For this purpose, we studied the removal of CPAs from articular cartilage *in situ*
111 in osteochondral dowels vitrified with our recently developed technique. To do this, we
112 measured the change in removal solution osmolality over time. We hypothesized that a
113 relationship between removal solution volume and time required for CPA removal could
114 be identified to aid in the clinical application of this technique.

115

116 **Material and Methods**

117 Using a hand-held coring device, osteochondral dowels (OCD, full thickness articular
118 cartilage on a bone base) were obtained from the weight bearing portion of distal femoral
119 condyles of patients undergoing total knee arthroplasty in Edmonton, Canada. Patient
120 information, including, age, gender, weight, height, medical diseases and smoking status
121 was recorded. OCDs obtained were placed in a Dulbecco's Phosphate Buffer Saline
122 (PBS) solution (pH7.1) and stored at 4 °C until they were either vitrified (an experimental
123 group) or used as controls.

124

125 OCDs were vitrified using the 6.5M Me₂SO/glycerol/propylene glycol/ethylene glycol
126 (DGPE) protocol developed by Jomha et al.[17] resulting in a concentration of 6.5M
127 CPA within the matrix at the end of the protocol. Briefly, the dowels were sequentially
128 placed in 6M Me₂SO for 1hr 30min at 0 °C; 6M glycerol and 2.4375M Me₂SO for 3hr
129 40min at 0 °C; 6M propylene glycerol, 2.4375M Me₂SO and 1.625 M glycerol for 3hr at
130 -10 °C; and finally 6M ethylene glycol, 2.4375M Me₂SO, 1.625 M glycerol, and
131 0.8125M propylene glycerol for 1hr 20 min at -15 °C. Dowels were then placed in a
132 storage solution containing 2.4375M Me₂SO, 1.625 M glycerol, 0.8125M propylene
133 glycerol, and 1.625 M ethylene glycol in 15ml polypropylene BD Falcon Centrifuge
134 Tubes (VWR International LLC). The tubes were then immersed in liquid nitrogen (LN₂)
135 and kept at -196 °C until later use.

136

137 Five vitrified OCD samples, from five patients were selected randomly for the
138 experiment. Tubes containing the vitrified dowels were removed from LN₂ and placed in
139 a water bath of 37 °C until the solidified storage solution melted. The tubes were left in
140 the water bath until used (time range: 5-7 minutes). The dowels were blot-dried using
141 Kimwipe tissue (Kimberly-Clark, Roswell, GA), and the volume of each dowel was
142 calculated using the average of heights measured from 3 different points.

143

144 The primary experiment consisted of an experimental and a control group. In the
145 experimental group, three 10 mm diameter OCDs were immersed sequentially into five
146 15 mL conical centrifuge tubes, each containing 10ml X-VIVO at 4 °C for 30 minutes.
147 The osmolality of the removal solution was recorded at 0, 1, 3, 5, 10 and 30 min. A

148 'μOSMETTE' micro-osmometer (Precision Systems, Natick, MA) was used to measure
149 the osmolality of a 50μl sample of the removal solution. The extracted solution was
150 replaced after each reading. A magnetic stirring bar (size equal to, or smaller than, 8mm x
151 1.5mm) was placed at the bottom of each tube to aid the mixing of the solution. The tubes
152 were kept in a plastic rack, centered on a stirrer. After 30 minutes in one tube, the dowel
153 was removed and dried, weighed and immersed in the next conical centrifuge tube
154 containing 10 mL X-VIVO. Again, using the same procedure, the change in osmolality
155 was measured at the same time intervals. This procedure was repeated 5 times in total
156 with the exception of the last immersion, which lasted for only 5 minutes. After the last
157 immersion, the dowels were dried and weighed.

158

159 The experimental control consisted of two fresh 10 mm diameter osteochondral samples
160 from two different donors immersed in 10 mL X-VIVO with the experimental protocol
161 performed in the same fashion with osmolality measurements done at the same time
162 intervals. However, the control dowels were immersed sequentially into two X-VIVO
163 tubes instead of five tubes.

164

165 In order to study the effect of increasing the volume of the removal solution on the rate of
166 CPA efflux, a secondary experiment was completed in a similar fashion to the primary
167 experiment using two 10mm diameter OCDs placed in subsequent removal solution
168 washes of 20 ml of X-VIVO (as opposed to 10ml in the primary experiment).

169

170 The change in osmolality (measured osmolality minus original removal solution
171 osmolality) was normalized to the calculated volume of the dowel (Δ Osmolality/ml
172 dowel). The average and standard error of the measurements was recorded and plotted
173 against time.

174

175 **Results**

176 Five vitrified osteochondral dowels and two fresh dowels from seven total knee
177 arthroplasty patients were used for the experiment as described in the Materials &
178 Methods section. The ages of the patients ranged from 55 to 77 (mean = 67.6). Of the 7
179 patients, 4 were males and 3 were females. The volumes of the dowels used for the
180 primary and secondary experiments and for experimental controls were 0.57 ± 0.06 mL,
181 0.56 ± 0.01 mL, and 0.82 ± 0.01 mL, respectively.

182 The results for the primary experiment (Figure 1), the secondary experiment (Figure 2)
183 and the control samples (Figure 3) are shown below. In both experiments, the initial rate
184 of change in osmolality of the removal solution per dowel volume was large in each
185 wash. Subsequently, the rate of change in osmolality decreased with time and subsequent
186 washes until a plateau was reached. The plateau was considered to be reached when the
187 change in osmolality of the removal solution was less than the change in osmolality of
188 the control samples. Immersing the fresh dowels in the control solution resulted in
189 minimal changes in the osmolality of the removal solution (0 to 15.44 mOsmol/ mL).

190

191 The number of washes required to remove CPA from vitrified dowels differed between
192 the experiments. In the primary experiment, the osmolality stabilized during the 4th

193 immersion. The 5th immersion confirmed that the plateau had been obtained (Figure 1).
194 When the volume of the removal solution was doubled, osmolality stabilized during the
195 third immersion. The 5th immersion was not carried out since no change in osmolality
196 was evident during the 4th immersion (Figure 2). The ratio of the volume of dowel to the
197 volume of removal solution was 1:17.4 in the primary experiment and 1:36.0 in the
198 secondary experiment.

199

200 **Discussion**

201 An effective protocol to vitrify intact human articular cartilage has recently been
202 developed by our group[17]. Removal of the CPAs from vitrified articular cartilage is
203 mandatory before the clinical use of this tissue to limit the potential toxic effect of CPAs
204 on the local cartilage cells and to the patient systemically. Interestingly, there are limited
205 guidelines regarding safety levels of CPAs in the body. The American Association of
206 Blood Banks (AABB) states: “*care should be taken not to exceed 1 mL of DMSO per*
207 *kilogram of recipient weight per day administration*” when transplanting bone marrow
208 cells[1]. Using this recommendation, the acceptable amount of CPA in a 70 kg person is
209 70 ml. With respect to transplantation of orthopaedic joint tissues, it is highly unlikely
210 that it would even be possible to have 70ml of CPAs within the transplanted tissue given
211 the relatively small volume of the transplanted tissue. Even though systemic toxicity is
212 highly unlikely, it is important to remove as much CPAs as possible to limit local
213 toxicity. Therefore we need to know how long it takes to remove essentially all of the
214 CPA from the transplantable tissue.

215

216 The results of the experiment show the number of washes required to remove CPAs from
217 vitrified dowels using multiple immersions in X-VIVO, each for 30 minutes based on the
218 volume of the diluting solution. In the primary experiment, four washes were required to
219 remove all CPA from vitrified cartilage. In the secondary experiment, when the ratio of
220 volume of dowel to volume of removal solution was decreased, only three washes were
221 required. The efflux was rapid in the first wash for both experiments. The efflux rate then
222 decreased with subsequent washes until a plateau was reached indicating the efflux of
223 most of the CPA. Based on the information provided here, it is reasonable to assume that
224 essentially all of the CPAs are removed after 4 washes in X-VIVO for 30 minutes when
225 the ratio of tissue to removal solution is $1:36 < x \leq 1:17$. Only 3 washes are required
226 when the ratio is less than or equal to 1:36.

227

228 As a further check that the majority of CPA has been removed from the dowel by the end
229 of all immersions, a rough mole balance can be performed. It is important to note for this
230 mole balance that the dowel is made up of both cartilage and bone and that these two
231 biomaterials have different capacities to hold CPA. The number of moles of CPA
232 removed by the end of all immersions can be found by summing the end average
233 osmolalities (this assumes that the removal solutions are dilute, which is a good
234 assumption), dividing by 1000 to convert units from osmoles per litre to osmoles per mL)
235 and multiplying by the number of mLs in the removal solution (since we need moles per
236 total removal solution). For example, in the case of the primary experiment, the total
237 CPA found in the removal solutions is $163.4 + 41.5 + 26.7 + 17.8 + 15.5 = 265$ mmolal
238 or 0.265 mmoles/mL or 2.65 mmoles in 10 mL. This 2.65 mmoles of CPA were

239 originally in the 1 mL of dowel. Note that all osmolality data is per mL of dowel in order
240 to be able to average different dowels with different volumes. To convert this mmoles per
241 total dowel volume into a CPA loading molarity, requires knowledge of what fraction of
242 the dowel holds solution. Assuming that the native water content can be used as a rough
243 measure of fraction of the biomaterial that can be taken up by CPA solution, we use a
244 water content (or solution fraction) for human femoral condyle articular cartilage of 77.6
245 %[23] and for human femur bone of 12.8%[30]. Then the original sample molarity is
246 computed by the equation below:

247

$$\text{Sample molar CPA} = \frac{2.65 \text{ mmoles}}{\text{sample solution volume in mL}}$$

248

$$= \frac{2.65 \text{ mmoles}}{1 \text{ mL} [\text{cartilage fraction} \times 0.776 + \text{bone fraction} \times 0.128]}$$

249

250 The dowels used in this experiment were not separated into their constituent cartilage and
251 bone portions. However, if we assume that the dowel started with 6.5 Molar CPA in the
252 solution space, we can find what cartilage fraction satisfies the above equation. From the
253 equation it was found for the primary experiment that if the samples were on average
254 43% cartilage and 57% bone, the mole balance would be satisfied and the amount of CPA
255 removed during the immersions would equal all the CPA that started in the dowel. Since
256 the average dowel height in the primary experiment was 7.3 mm, this would mean that
257 the average cartilage thickness would be predicted to be 3.1 mm if the mole balance was
258 satisfied. A similar rough mole balance for the secondary experiment indicates that the

259 average cartilage thickness would be predicted to be 1.8 mm if the mole balance was
260 satisfied. The actual thicknesses of the cartilage portion of the OCDs in this study were
261 not measured; however cartilage thickness measurements at various locations within
262 osteochondral dowels from the same tissue source (but different patients) in a separate
263 study yielded thicknesses ranging from 1.7 mm to 3.3 mm. Since the thicknesses
264 predicted by the mole balances give a reasonable estimation of the actual human cartilage
265 thickness in experiments, we can conclude that a rough mole balance supports the
266 assertion that the majority of CPA is removed after completion of all immersions.

267

268 It is interesting to note from a practical standpoint that although it takes 9.5 hours to load
269 the CPA into the dowels to vitrify them, with the removal procedure we propose it takes,
270 at most, only 2.0 hours to remove the CPA. This is because the removal happens at a
271 higher temperature and CPA permeation rates are exponentially dependent on
272 temperature and also because replacing the removal solution with fresh CPA-free
273 removal solution every 30 minutes maintains a high driving force for removal.

274

275 In conclusion, the amount of CPA within the cartilage matrix after vitrification is
276 acceptable for transplantation with current guidelines. Removal of essentially all of the
277 CPA is easily obtained with 3 or 4 washes in X-VIVO for 30 minutes each depending on
278 the tissue to removal solution volume ratio.

279

280 **Acknowledgements**

281 This research was funded by Canadian Institutes for Health Research (MOP 93805).
282 JAWE holds a Canada Research Chair in Thermodynamics. We thank Xianpei Zhou for
283 his technical support.
284
285

286 **Figure Legends**

287 Figure 1: Graphs showing the change in osmolality of the removal solution in the primary
288 experiment (immersion in subsequent washes of 10 ml of X-VIVO). It is important to
289 note the rapid osmolality change early on that decreases with time with a resultant plateau
290 during the 4th immersion. $N = 3 \pm \text{SEM}$.

291

292 Figure 2: Graphs showing the change in osmolality of the removal solution in the
293 secondary experiment (immersion in subsequent washes of 20 mL of X-VIVO). Once
294 again there was a rapid increase in the osmolality change at early time points. The
295 osmolality change plateaued during the 3rd immersion. $N = 2 \pm \text{SEM}$. (Note that for $N =$
296 2, the SEM simply shows exactly the range of the two results.)

297

298 Figure 3: Graphs showing the change in osmolality of the control samples. Note that
299 there was minimal change in osmolality at any time point. $N = 2 \pm \text{SEM}$. (Note that for $N =$
300 2, the SEM simply shows exactly the range of the two results.)

301

302

303

304

305

306 **References**

- 307 [1] Circular of information for the use of cellular therapy products, American
308 Association of Blood Banks, 2009.
- 309 [2] A. Abazari, J.A. Elliott, G.K. Law, L.E. McGann, and N.M. Jomha, A biomechanical
310 triphasic approach to the transport of nondilute solutions in articular
311 cartilage. *Biophys J* 97, (2009) 3054-64.
- 312 [3] A. Abazari, J.A. Elliott, L.E. McGann, and R.B. Thompson, MR spectroscopy
313 measurement of the diffusion of dimethyl sulfoxide in articular cartilage and
314 comparison to theoretical predictions. *Osteoarthritis Cartilage* 20, (2012)
315 1004-10.
- 316 [4] A. Abazari, R.B. Thompson, J.A. Elliott, and L.E. McGann, Transport phenomena in
317 articular cartilage cryopreservation as predicted by the modified triphasic
318 model and the effect of natural inhomogeneities. *Biophys J* 102, (2012) 1284-
319 93.
- 320 [5] R.T. Allen, C.M. Robertson, A.T. Pennock, W.D. Bugbee, F.L. Harwood, V.W. Wong,
321 A.C. Chen, R.L. Sah, and D. Amiel, Analysis of stored osteochondral allografts
322 at the time of surgical implantation. *Am J Sports Med* 33, (2005) 1479-84.
- 323 [6] K.A. Almansoori, V. Prasad, J.F. Forbes, G.K. Law, L.E. McGann, J.A. Elliott, and
324 N.M. Jomha, Cryoprotective agent toxicity interactions in human articular
325 chondrocytes. *Cryobiology*, (2012).
- 326 [7] A.F. Anderson, and M.J. Pagnani, Osteochondritis dissecans of the femoral
327 condyles. Long-term results of excision of the fragment. *Am J Sports Med* 25,
328 (1997) 830-834.
- 329 [8] P.P. Aubin, H.K. Cheah, A.M. Davis, and A.E. Gross, Long-term followup of fresh
330 femoral osteochondral allografts for posttraumatic knee defects. *Clin Orthop*,
331 (2001) S318-327.
- 332 [9] B. Bakar, E.A. Kose, S. Sonal, A. Alhan, K. Kilinc, and I.S. Keskil, Evaluation of the
333 neurotoxicity of DMSO infused into the carotid artery of rat. *Injury*, (2011).
- 334 [10] S.T. Ball, D. Amiel, S.K. Williams, W. Tontz, A.C. Chen, R.L. Sah, and W.D. Bugbee,
335 The effects of storage on fresh human osteochondral allografts. *Clin Orthop*
336 *Relat Res*, (2004) 246-52.
- 337 [11] K.G. Brockbank, Z.Z. Chen, and Y.C. Song, Vitrification of porcine articular
338 cartilage. *Cryobiology* 60, (2010) 217-21.
- 339 [12] A.A. De Smet, O.A. Ilahi, and B.K. Graf, Untreated osteochondritis dissecans of
340 the femoral condyles: prediction of patient outcome using radiographic and
341 MR findings. *Skeletal Radiol* 26, (1997) 463-467.
- 342 [13] A.E. Gross, W. Kim, F. Las Heras, D. Backstein, O. Safir, and K.P. Pritzker, Fresh
343 osteochondral allografts for posttraumatic knee defects: long-term followup.
344 *Clin Orthop Relat Res* 466, (2008) 1863-70.
- 345 [14] A.R. Hipkiss, Proteotoxicity and the contrasting effects of oxaloacetate and
346 glycerol on *Caenorhabditis elegans* life span: a role for methylglyoxal?
347 *Rejuvenation Res* 13, (2010) 547-51.
- 348 [15] S.W. Jacob, and J.C. de la Torre, Pharmacology of dimethyl sulfoxide in cardiac
349 and CNS damage. *Pharmacol Rep* 61, (2009) 225-35.

- 350 [16] D. Jammalamadaka, and S. Raissi, Ethylene glycol, methanol and isopropyl
351 alcohol intoxication. *Am J Med Sci* 339, (2010) 276-81.
- 352 [17] N.M. Jomha, J.A. Elliott, G.K. Law, B. Maghdoori, J. Fraser Forbes, A. Abazari, A.B.
353 Adesida, L. Laouar, X. Zhou, and L.E. McGann, Vitrification of intact human
354 articular cartilage. *Biomaterials* 33, (2012) 6061-8.
- 355 [18] N.M. Jomha, J.A.W. Elliott, G.K. Law, B. Maghdoori, J.F. Forbes, A. Abazari, A.B.
356 Adesida, L. Laouar, X. Zhou, and L.E. McGann, Vitrification of intact human
357 articular cartilage. *Biomaterials* In press., (2012).
- 358 [19] N.M. Jomha, G. Lavoie, K. Muldrew, N.S. Schachar, and L.E. McGann,
359 Cryopreservation of intact human articular cartilage. *J Orthop Res* 20, (2002)
360 1253-5.
- 361 [20] N.M. Jomha, G.K. Law, A. Abazari, K. Rekieh, J.A. Elliott, and L.E. McGann,
362 Permeation of several cryoprotectant agents into porcine articular cartilage.
363 *Cryobiology* 58, (2009) 110-4.
- 364 [21] N.M. Jomha, A.D. Weiss, J. Fraser Forbes, G.K. Law, J.A. Elliott, and L.E. McGann,
365 Cryoprotectant agent toxicity in porcine articular chondrocytes. *Cryobiology*
366 61, (2010) 297-302.
- 367 [22] R.K. Koiri, and S.K. Trigun, Dimethyl sulfoxide activates tumor necrosis
368 factor-alpha-p53 mediated apoptosis and down regulates D-fructose-6-
369 phosphate-2-kinase and lactate dehydrogenase-5 in Dalton's lymphoma in
370 vivo. *Leuk Res* 35, (2011) 950-6.
- 371 [23] R. Sharma, G.K. Law, K. Rekieh, A. Abazari, J.A. Elliott, L.E. McGann, and N.M.
372 Jomha, A novel method to measure cryoprotectant permeation into intact
373 articular cartilage. *Cryobiology* 54, (2007) 196-203.
- 374 [24] A.U. Smith, Survival of frozen chondrocytes isolated from cartilage of adult
375 mammals. *Nature* 205, (1965) 782-784.
- 376 [25] Y.C. Song, Y.H. An, Q.K. Kang, C. Li, J.M. Boggs, Z. Chen, M.J. Taylor, and K.G.
377 Brockbank, Vitreous preservation of articular cartilage grafts. *J Invest Surg*
378 17, (2004) 65-70.
- 379 [26] W.L. Tontz, Jr., W.D. Bugbee, and M.E. Brage, Use of allografts in the
380 management of ankle arthritis. *Foot Ankle Clin* 8, (2003) 361-73, xi.
- 381 [27] L. Wang, D.E. Pegg, J. Lorrison, D. Vaughan, and P. Rooney, Further work on the
382 cryopreservation of articular cartilage with particular reference to the
383 liquidus tracking (LT) method. *Cryobiology* 55, (2007) 138-47.
- 384 [28] A.D. Weiss, J.F. Forbes, A. Scheuerman, G.K. Law, J.A. Elliott, L.E. McGann, and
385 N.M. Jomha, Statistical prediction of the vitrifiability and glass stability of
386 multi-component cryoprotective agent solutions. *Cryobiology* 61, (2010)
387 123-7.
- 388 [29] S.K. Williams, D. Amiel, S.T. Ball, R.T. Allen, V.W. Wong, A.C. Chen, R.L. Sah, and
389 W.D. Bugbee, Prolonged storage effects on the articular cartilage of fresh
390 human osteochondral allografts. *J Bone Joint Surg Am* 85-A, (2003) 2111-20.
- 391 [30] Y.N. Yeni, C.U. Brown, and T.L. Norman, Influence of bone composition and
392 apparent density on fracture toughness of the human femur and tibia. *Bone*
393 22, (1998) 79-84.

394 [31] T. Zampolla, E. Spikings, T. Zhang, and D.M. Rawson, Effect of methanol and
395 Me₂SO exposure on mitochondrial activity and distribution in stage III
396 ovarian follicles of zebrafish (*Danio rerio*). *Cryobiology* 59, (2009) 188-94.
397
398

***Statement of Funding**

This research was funded by Canadian Institutes for Health Research (MOP 93805).

Conflict of Interest

The authors have no conflict of interest.

Figure 1




Figure 2




Figure 3

